APA (7th ed.) Citation

Armstrong, A. W., Augustin, M., Beaumont, J. L., Pham, T. P., Hudgens, S., Gordon, K. B., . . . Papp, K. A. (2024). Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials. Dermatology & Therapy, 14(8), 2235. https://doi.org/10.1007/s13555-024-01224-x

Chicago Style (17th ed.) Citation

Armstrong, April W., et al. "Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials." Dermatology & Therapy 14, no. 8 (2024): 2235. https://doi.org/10.1007/s13555-024-01224-x.

MLA (9th ed.) Citation

Armstrong, April W., et al. "Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials." Dermatology & Therapy, vol. 14, no. 8, 2024, p. 2235, https://doi.org/10.1007/s13555-024-01224-x.